Antisense oligonucleotides as therapeutic agents

被引:50
作者
Alama, A
Barbieri, F
Cagnoli, M
Schettini, G
机构
[1] Department of Preclinical Oncology, Laboratory of Pharmacology, Ist. Naz. per la Ricerca sul Cancro, Genova
[2] Department of Preclinical Oncology, Laboratory of Pharmacology, Ist. Naz. per la Ricerca sul Cancro, 16132 Geneva
关键词
antisense oligonucleotides; gene expression; oncogenes; viral targets;
D O I
10.1006/phrs.1997.0227
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The potential for modulating gene expression by the use of antisense oligonucleotides has become increasingly interesting in recent years. Antisense oligonucleotides are complementary nucleic acid fragments that hybridize to target sequences within RNA to form a DNA-RNA duplex, resulting in the block of translation of messenger RNA into the protein. Advances in chemistry and molecular biology have provided the basis to develop antisense oligodeoxynucleotides and improve their selectivity, stability and specificity of action. The antisense technology has been extensively used in vitro and in vivo as a tool to study the regulatory mechanisms in biologic processes and as potential therapeutic agents in cancer, viral infections and genetic disorders. In the present review, the various approaches for the use of antisense molecules in oncology, virology, genetic and inflammatory diseases are described; several studies, supporting the in vitro and in vivo applications of this technology, are also presented. Moreover, the potential clinical use of antisense therapies is discussed. (C) 1997 The Italian Pharmacological Society.
引用
收藏
页码:171 / 178
页数:8
相关论文
共 53 条
[1]   Antisense oligonucleotides: Towards clinical trials [J].
Agrawal, S .
TRENDS IN BIOTECHNOLOGY, 1996, 14 (10) :376-387
[2]   ABSORPTION, TISSUE DISTRIBUTION AND IN-VIVO STABILITY IN RATS OF A HYBRID ANTISENSE OLIGONUCLEOTIDE FOLLOWING ORAL-ADMINISTRATION [J].
AGRAWAL, S ;
ZHANG, XS ;
LU, ZH ;
ZHAO, H ;
TAMBURIN, JM ;
YAN, YM ;
CAI, HY ;
DIASIO, RB ;
HABUS, I ;
JIANG, ZW ;
IYER, RP ;
YU, D ;
ZHANG, RW .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (04) :571-576
[3]   Anti-HIV therapy with antisense oligonucleotides and ribozymes: Realistic approaches or expensive myths? [J].
Akhtar, S ;
Rossi, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (02) :159-165
[4]   Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA [J].
Anderson, KP ;
Fox, MC ;
BrownDriver, V ;
Martin, MJ ;
Azad, RF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2004-2011
[5]  
AOKI K, 1995, CANCER RES, V55, P3810
[6]   ANTIVIRAL ACTIVITY OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE COMPLEMENTARY TO HUMAN CYTOMEGALOVIRUS RNA WHEN USED IN COMBINATION WITH ANTIVIRAL NUCLEOSIDE ANALOGS [J].
AZAD, RF ;
BROWNDRIVER, V ;
BUCKHEIT, RW ;
ANDERSON, KP .
ANTIVIRAL RESEARCH, 1995, 28 (02) :101-111
[7]   ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST P53 HAVE ANTIPROLIFERATIVE EFFECTS UNRELATED TO EFFECTS ON P53 EXPRESSION [J].
BARTON, CM ;
LEMOINE, NR .
BRITISH JOURNAL OF CANCER, 1995, 71 (03) :429-437
[8]   INHIBITION OF VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION IN-VITRO AND IN-VIVO BY C-MYC ANTISENSE OLIGODEOXYNUCLEOTIDES [J].
BENNETT, MR ;
ANGLIN, S ;
MCEWAN, JR ;
JAGOE, R ;
NEWBY, AC ;
EVAN, GI .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (02) :820-828
[9]   APTAMERIC INHIBITION OF P210(BCR-ABL) TYROSINE KINASE AUTOPHOSPHORYLATION BY OLIGODEOXYNUCLEOTIDES OF DEFINED SEQUENCE AND BACKBONE STRUCTURE [J].
BERGAN, R ;
CONNELL, Y ;
FAHMY, B ;
KYLE, E ;
NECKERS, L .
NUCLEIC ACIDS RESEARCH, 1994, 22 (11) :2150-2154
[10]   INHIBITORY EFFECTS OF ANTISENSE OLIGODEOXYNUCLEOTIDES TARGETING C-MYC MESSENGER-RNA ON SMOOTH-MUSCLE CELL-PROLIFERATION AND MIGRATION [J].
BIRO, S ;
FU, YM ;
YU, ZX ;
EPSTEIN, SE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :654-658